Table 2.
Follow-up data of patients
| Parameter | Drug | Mean (SD) | P* | ||
|---|---|---|---|---|---|
| First visit | Second visit | Third visit | |||
| BMI | Fenugreek | 29.16 (3.92) | 28.67 (3.96) | 28.54 (4.01) | F=(2, 44)=2.053, |
| Placebo | 28.38 (4.59) | 28.31 (4.90) | 28.16 (4.89) | P=0.155 | |
| Weight | Fenugreek | 88.54 (11.90) | 87.04 (11.92) | 86.65 (12.18) | F=(2, 44)=1.784, |
| Placebo | 80.41 (16.61) | 80.05 (16.99) | 79.64 (16.83) | P=0.190 | |
| Waist to hip ratio | Fenugreek | 1.05 (0.21) | 1.03 (0.20) | 1.04 (0.20) | F=(2, 44)=1.402, |
| Placebo | 0.96 (0.06) | 0.97 (0.06) | 0.97 (0.08) | P=0.257 | |
| Alanine aminotransferase | Fenugreek | 57.00 (17.18) | 56.00 (35.90) | 58.00 (37.06) | F=(2, 44)=1.006, |
| Placebo | 60.64 (24.90) | 58.09 (42.21) | 47.55 (36.80) | P=0.374 | |
| AST | Fenugreek | 34.38 (7.37) | 31.08 (12.00) | 32.77 (12.22) | F=(2, 44)=2.843, |
| Placebo | 37.00 (11.44) | 39.67 (21.31) | 29.82 (16.47) | P=0.081 | |
| ALK | Fenugreek | 221.08 (42.14) | 213.62 (33.81) | 218.77 (37.87) | F=(2, 44)=2.189, |
| Placebo | 248.64 (75.30) | 250.82 (84.92) | 228.18 (80.10) | P=0.137 | |
| Albumin | Fenugreek | 4.72 (0.40) | 4.62 (0.40) | 4.56 (0.23) | F=(2, 44)=0.806, |
| Placebo | 4.67 (0.34) | 4.70 (0.35) | 4.71 (0.28) | P=0.453 | |
| FBS | Fenugreek | 90.31 (12.95) | 93.85 (9.08) | 88.77 (10.23) | F=(2, 44)=1.191, |
| Placebo | 90.00 (14.04) | 84.64 (11.51) | 84.00 (13.02) | P=0.314 | |
| Triglyceride | Fenugreek | 167.85 (71.36) | 198.00 (94.80) | 166.77 (87.11) | F=(2, 44)=2.876, |
| Placebo | 173.82 (88.13) | 198.36 (119.14) | 242.18 (143.09) | P=0.067 | |
| Cholesterol | Fenugreek | 188.92 (26.30) | 189.38 (29.47) | 192.46 (19.53) | F=(2, 44)=1.534, |
| Placebo | 174.73 (43.90) | 187.55 (48.38) | 198.64 (53.19) | P=0.231 | |
| LDL | Fenugreek | 113.23 (24.93) | 118.08 (23.86) | 116.54 (25.23) | F=(2, 44)=1.766, |
| Placebo | 100.27 (33.93) | 109.64 (36.10) | 121.27 (40.50) | P=0.195 | |
| HDL | Fenugreek | 42.85 (8.91) | 46.23 (5.63) | 44.08 (8.36) | F=(2, 44)=1.193, |
| Placebo | 46.27 (11.28) | 45.36 (10.96) | 41.82 (7.31) | P=0.313 | |
| Uric acid | Fenugreek | 5.45 (1.49) | 5.56 (1.39) | 6.10 (1.38) | F=(2, 44)=0.896, |
| Placebo | 4.49 (1.21) | 4.60 (1.34) | 4.66 (1.39) | P=0.416 | |
| Creatinine | Fenugreek | 0.96 (0.16) | 0.91 (0.13) | 1.01 (0.10) | F=(2, 44)=3.776, |
| Placebo | 0.92 (0.13) | 0.91 (0.13) | 0.87 (0.16) | P=0.031 | |
| Hemoglobin | Fenugreek | 15.20 (1.32) | 15.16 (1.60) | 15.34 (1.55) | F=(2, 44)=0.356, |
| Placebo | 15.51 (1.36) | 15.33 (1.04) | 15.37 (1.00) | P=0.702 | |
| White blood cells | Fenugreek | 6.48 (1.41) | 6.21 (1.17) | 6.08 (0.83) | F=(2, 44)=2.215, |
| Placebo | 6.86 (1.60) | 7.21 (2.52) | 7.59 (2.44) | P=0.121 | |
| Platelet | Fenugreek | 216.85 (64.16) | 221.15 (63.96) | 214.69 (62.94) | F=(2, 44)=0.638, |
| Placebo | 241.27 (35.29) | 257.18 (50.71) | 248.45 (54.35) | P=0.533 | |
| Liver stiffness measure | Fenugreek | 5.30 (0.78) | NP | 5.88 (1.45) | F=(1, 17)=1.072, |
| Placebo | 5.32 (1.89) | NP | 5.20 (1.62) | P=0.315 | |
| CAP score | Fenugreek | 309.10 (39.06) | NP | 273.90 (47.75) | F=(1, 17)=3.023, |
| Placebo | 286.56 (54.04) | NP | 281.44 (48.18) | P=0.100 | |
| Steatosis percent | Fenugreek | 68.30 (22.90) | NP | 46.70 (28.16) | F=(1, 17)=4.014, |
| Placebo | 50.67 (32.69) | NP | 52.67 (26.55) | P=0.061 | |
*Two-way repeated measures ANOVA. NP=Not performed, AST=Aspartate transaminase, ALK=Alkaline phosphatase, FBS=Fasting blood sugar, LDL=Low-density lipoprotein, HDL=High-density lipoprotein, CAP=Controlled attenuation parameter, BMI=Body mass index, SD=Standard deviation